Top

Published in:

01-03-2008 | Original Article

Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue

Authors: Susanne Haas, Tjoung-Won Park, Jens Claus Hahne, Hans-Peter Fischer

Published in: Virchows Archiv | Issue 3/2008

Abstract

The urokinase-type plasminogen activator (uPA) and the plasminogen activator inhibitor-1 (PAI-1) are involved in tumor invasion and metastasis as well as wound healing and inflammation. We investigated the impact of tissue injury by preoperative sampling on the level of uPA/PAI-1 in paraffin tissue of 55 breast cancer cases by immunohistochemistry. The tumor area surrounding the biopsy channel was compared with distant intact tumor tissue. uPA and PAI-1 were constantly expressed by the tumor cells. Fibroblastic expression was higher in the tumor area surrounding the biopsy channel than in intact tissue with 47 vs 29 positive cases for uPA (p < 0.001) and 35 vs 25 positive cases for PAI-1 (p = 0.055). A decrease in fibroblastic enzyme expression from the biopsy area to the intact tumor tissue was seen in 21 cases for uPA and 16 cases for PAI-1. This difference was most evident in cases with an interval of 6 days and longer between biopsy and surgery. In conclusion, fibroblastic inflammatory reaction around the biopsy channel affects stromal uPA and PAI-1 expression, which possibly leads to falsely increased enzyme levels in ELISA. Tissue specimen for ELISA analysis should not be taken from the tumor area around the biopsy channel in the resection specimen.

Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57(1):25–40PubMedCrossRef

Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator in cancer metastasis: a review. Int J Cancer 72:1–22PubMedCrossRef

Camps JL, Chang SM, Hsu TC, Freeman MR, Hong SJ, Zhau HE, von Eschenbach AC, Chung LW (1990) Fibroblast mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA 87:75–79PubMedCrossRef

Dublin E, Hanby A, Patel NK, Liebman R, Barnes D (2000) Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Am J Pathol 157:1219–1227PubMed

Duffy MJ, Reilly D, O’Sullivan C, O’Higgins N, Fennelly JJ, Andreasen P (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50:6827–6829PubMed

Ferrier CM, de Witte HH, Straatman H, van Tienoven DH, van Geloof WL, Rietveld FJR, Sweep CGJ, Ruiteer DJ, van Muijen GNP (1999) Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br J Cancer 79:1534–1541PubMedCrossRef

Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, de Boer A, Welvaart K, de Velde CJ, van Krieken JH, Verheijen JH, Lamers CB (1994) Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54:4065–4071PubMed

Harbeck N, Kates RE, Look MP, Meijer-van Gelder ME, Klijn JGM, Jänicke F, Krüger A, Kiechle M, Schmitt M, Foekens JA (2002) Enhanced benefit from adjuvant systemic chemotherapy in breast cancer patients classified high risk according to uPA and PAI-1 (n = 3424). Cancer Res 62:4617–4622PubMed

Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M, for the German Chemo N0 Study group (2001) Randomized adjuvant chemotherapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type I. J Natl Cancer Inst 93:913–920PubMedCrossRef

10.

Lee AHS, Gillett CE, Ryder K, Fentiman IS, Miles DW, Millis RR (2006) Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology 48:692–701PubMedCrossRef

11.

Liotta LA, Kohn EC (2001) The microenvironment of the tumour–host interface. Nature 411:375–379PubMedCrossRef

12.

Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CGJ, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Mander P, fiets E, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LVAM, Klijn JGM, O’Higgins NO, Eppenberger U, Jänicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Institute 94:116–128

13.

Nielsen BS, Sehested M, Suun S, Rank F, Timshel S, Rygaard J, Johnsen M, Dano K (2001) Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 81:1485–1501PubMed

14.

Olumi AF, Dazin P, Tlsty TD (1998) A novel coculture technique demonstrates that normal human prostatic fibroblasts contribute to tumor formation of LNCaP cells by retarding cell death. Cancer Res 58:4525–4530PubMed

15.

Pappot H, Gardsvoll H, Romer J, Pedersen AN, Grondahl-Hansen J, Pyke C, Brunner N (1995) Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe Seyler 376(5):259–267PubMed

16.

Pyke C, Ralfkiaer E, Tryggvason K, Dano K (1993) Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142:359–365PubMed

17.

Schäfer BM, Maier K, Eickhoff U, Todd RF, Kramer MD (1994) Plasminogen activation in healing human wounds. Am J Pathology 144:1269–1280

18.

Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L, Graeff H (1992) Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler 373(7):611–22PubMed

19.

Sweep CGJ, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJTM, Schmitt M, Duffy MJ, Jänicke F, Kramer MD, Foekens JA, Brünner N, Brugal G, Pedersen AN, Benraad TJ (1998) External quality assessment of trans-European multicentre antigen determinations (ELISA) of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PI-1) in human breast cancer tissue extracts. Br J Cancer 78:1434–1441PubMed

Title: Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue
Authors: Susanne Haas
Tjoung-Won Park
Jens Claus Hahne
Hans-Peter Fischer
Publication date: 01-03-2008
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 3/2008
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-007-0563-8

At a glance: The STEP trials

Springer Medicine

Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Renal oncocytoma with and without intravascular extension into the branches of renal vein have the same morphological, immunohistochemical and genetic features

A case of pararenal PEComa with extensive bone metaplasia

Cut-resistant protective gloves in pathology—effective and cost-effective

Consistent numerical chromosome aberrations in thecofibromas of the ovary

A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathology

Thymoma with ganglioneuroblastomatous component: case report